Sanofi’s Paul Hudson pays $357M to buy a biotech partner, adding an NK strategy in the latest move to beef up cancer R&D

John Carroll

Editor & Founder

A year after Amsterdam-based Kiadis underwent a wrenching reorganization after its lead drug went pffffffft at the EMA, battering the share price and butchering …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sanofi’s Paul Hudson pays $357M to buy a biotech partner, adding an NK strategy in the latest move to beef up cancer R&D

John Carroll

Editor & Founder

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Can Bill Anderson save Bayer?

Updated: Lilly joins Trump administration to announce $27B manufacturing commitment

Verve is latest gene editing company to suffer setback, as Vertex walks away from pact

CDC is investigating five hospitalizations after use of Valneva’s chikungunya vaccine

FDA meeting to pick next winter's flu shot is canceled, in ominous sign for US vaccine policy

How AI can address ongoing challenges in the life sciences industry

Sanofi’s Paul Hud­son pays $357M to buy a biotech part­ner, adding an NK strat­e­gy in the lat­est move to beef up can­cer R&D

Editor & Founder

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Sanofi’s Paul Hudson pays $357M to buy a biotech partner, adding an NK strategy in the latest move to beef up cancer R&D